<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02075697</url>
  </required_header>
  <id_info>
    <org_study_id>Biobadaderm</org_study_id>
    <secondary_id>Biobadaderm</secondary_id>
    <nct_id>NCT02075697</nct_id>
  </id_info>
  <brief_title>Spanish Registry of Systemic Treatments in Psoriasis</brief_title>
  <acronym>Biobadaderm</acronym>
  <official_title>Spanish Registry of Systemic Treatments in Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Academia Española de Dermatología</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Agencia Española de Medicamentos y Productos Sanitarios</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen, LP</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Academia Española de Dermatología</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of Biobadaderm is a to study the safety of systemic therapy in psoriasis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Spanish Registry for Adverse Events of Biological Therapies in Dermatology (BIOBADADERM)
      was launched in October 2008, as a pharmacovigilance effort for psoriatic patients. The
      registry is managed by the Foundation of the Spanish Academy of Dermatology and Venereology
      (AEDV). BIOBADADERM has been promoted by the AEDV, in collaboration with the Spanish Agency
      for Medicines and Health Products (AEMPS) and the Research Unit of the Spanish Foundation of
      Rheumatology (FER) and the Research Unit of the Fundacion AEDV. BIOBADADERM is part of
      PSONET, a European network for sharing data from records of patients treated with biologics.

      BIOBADADERM is a prospective cohort of patients receiving biologic drugs that can be compared
      with another cohort of patients receiving other systemic treatments. One of the cohorts is
      made up of all consecutive psoriasis patients who begin any biological therapy (including
      infliximab (INF), etanercept (ET), efalizumab (EFA), adalimumab (ADA), rituximab (RTX) and
      ustekinumab (UTK)) in each centre. The control cohort consists of psoriasis patients who
      begin, for the first time, a nonbiologic systemic treatment (methotrexate, cyclosporine or
      acitretin).

      The objectives of BIOBADADERM are:

        -  Identify adverse events (AEs) occurring during the relevant treatment with biologic
           therapies, and estimate their frequency;

        -  Identify unexpected AEs, particularly those that may occur after long periods of
           exposure;

        -  Identify relevant AEs that arise after discontinuation of treatment;

        -  Estimate the relative risk of developing AEs with biologic therapies in patients with
           psoriasis compared to psoriatic patients exposed to other systemic (non-biological); and

        -  Identify risk factors for AEs in patients with these treatments.

      Data were initially collected retrospectively in hospitals with a list of all patients who
      had received biologic drugs between 1 January 2005 and 30 October 2008 and check-ups with a
      frequency of at least every 6 months. Since 2008, data have been captured prospectively.

      The database includes demographic, diagnostic and comorbidity data, the treatments performed,
      the duration of these treatments and the adverse effects that arise (coded using MedDRA). In
      its first year, 632 patients from 12 centers participated with BIOBADADERM. In October 2012
      the registry had data from 1,793 patients, which includes 946 patients on biologic treatments
      and 847 patients on non-biologic systemic treatments.

      Data for each patient have been reversibly anonymized and entered into a database. Data are
      entered over the Internet (http://biobadaser.ser.es/biobadaderm/). The data are stored in the
      Research Department of the Spanish Rheumatology Foundation.

      The included data are continually revised online by a study monitor to verify consistency,
      comprehensiveness, and absence of anomalies. A follow-up visit is made every year during
      which a sample of the the data in the database are compared with those in the clinical
      records.

      Sample size was calculated to give, after 5 years, 80% power and using alfa level= 0.05, to
      detect a rate ratio of 2 in events with 4.1 cases per 1000 person-years, or a rate ratio of 5
      in events with 0.5 cases per 1000 person-years. Further calculations are available in the
      study protocol (https://biobadaser.ser.es/biobadaderm/index.html).

      Default value in each variable is &quot;missing&quot;. Plans for missing data in analysis depend on the
      aim of analysis but with a preference for the most conservative ( in terms of patient safety)
      analysis.

      Analysis consists of description of rates, rate ratios and adjusted rate ratios (adjusted for
      possible confounders, age always included).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Serious Adverse Events</measure>
    <time_frame>an expected mean follow-up of 5 years</time_frame>
    <description>Lag windows used to link events and therapy are described in the study web site.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other adverse events leading to changes in drug therapy or unexpected visits to health provider</measure>
    <time_frame>an expected mean follow-up of 5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mortality</measure>
    <time_frame>an expected mean follow-up of 5 years</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1887</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Biologic drugs</arm_group_label>
    <description>Drug data include biologic therapy (including infliximab (INF), etanercept (ET), efalizumab (EFA), adalimumab (ADA), and ustekinumab (UTK).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Classic systemic therapy</arm_group_label>
    <description>Non-biological systemic treatment (methotrexate, cyclosporine and acitretin) Phototherapy was accepted as systemic therapy only in the small group of patients retrospectively included(PUVA, UVB 311).</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Psoriasis patients requiring systemic therapy.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For biologics group: all consecutive psoriasis patients who begin any biological
             therapy

          -  For classic systemic group: the next psoriasis patients who begin, for the first time,
             a nonbiologic systemic treatment (after including a patient in the biologics group)

        Exclusion Criteria:

          -  Intention of moving to a different geographic area in the next three months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esteban Daudén, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de La Princesa- Madrid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ignacio Garcia-Doval, PhD, MScEpid</last_name>
    <phone>34- 915446284</phone>
    <email>investigacion@aedv.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitari German Trias y Pujol.</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundación Hospital Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar. IMAS</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Gran Canaria Dr Negrín</name>
      <address>
        <city>Las Palmas</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Victoria</name>
      <address>
        <city>Málaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen Macarena de Sevilla</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>https://biobadaderm.fundacionpielsana.es/biobadaderm/cgi-bin/upload/publicaciones.aspx</url>
  </link>
  <results_reference>
    <citation>Rivera R, García-Doval I, Carretero G, Daudén E, Sánchez-Carazo J, Ferrándiz C, Herrera E, Alsina M, Ferrán M, López-Estebaranz JL, Gómez F, Herranz JM, Carrascosa JM, Vanaclocha F; miembros del grupo BIOBADADERM. [BIOBADADERM, the Spanish Registry of Adverse Events Associated with Biologic Drugs in Dermatology: first report]. Actas Dermosifiliogr. 2011 Mar;102(2):132-41. doi: 10.1016/j.ad.2010.10.016. Epub 2011 Mar 4. Spanish.</citation>
    <PMID>21377137</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, Alsina M, Herrera-Ceballos E, Gómez-García FJ, Ferrán M, López-Estebaranz JL, Hernanz JM, Belinchón-Romero I, Vilar-Alejo J, Rivera R, Carrascosa JM, Carazo C. Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials. Arch Dermatol. 2012 Apr;148(4):463-70. doi: 10.1001/archdermatol.2011.2768.</citation>
    <PMID>22508869</PMID>
  </results_reference>
  <results_reference>
    <citation>Sánchez-Moya AI, García-Doval I, Carretero G, Sánchez-Carazo J, Ferrandiz C, Herrera Ceballos E, Alsina M, Ferrán M, López-Estebaranz JL, Gómez-García F, De la Cueva Dobao P, Carrascosa JM, Vanaclocha F, Belinchón I, Peral F, Dauden E; BIOBADADERM Study Group. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: a study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2013 Nov;27(11):1366-74. doi: 10.1111/jdv.12011. Epub 2012 Nov 8.</citation>
    <PMID>23134268</PMID>
  </results_reference>
  <results_reference>
    <citation>Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, Herrera-Ceballos E, De la Cueva Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Peral F, Torrado R, Rivera R, Jiménez-Puya R, Mendiola MV, Ferrándiz C; BIOBADADERM Study Group. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol. 2014 Jul;28(7):907-14. doi: 10.1111/jdv.12208. Epub 2013 Jul 15.</citation>
    <PMID>23848131</PMID>
  </results_reference>
  <results_reference>
    <citation>Garcia-Doval I, Rustenbach SJ, Stern R, Dam TN, Cohen AD, Baker C, Spuls PI, Naldi L; Psonet Network. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. Br J Dermatol. 2013 Sep;169(3):710-4. doi: 10.1111/bjd.12344.</citation>
    <PMID>23551034</PMID>
  </results_reference>
  <results_reference>
    <citation>Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Carrascosa JM, Torrado R, Argila D, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015 May;29(5):858-64. doi: 10.1111/jdv.12688. Epub 2014 Sep 3.</citation>
    <PMID>25185962</PMID>
  </results_reference>
  <results_reference>
    <citation>Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastián F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina-Gibert M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Carazo C, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):156-63. doi: 10.1111/jdv.12492. Epub 2014 Mar 31.</citation>
    <PMID>24684267</PMID>
  </results_reference>
  <results_reference>
    <citation>García-Doval I, Pérez-Zafrilla B, Ferrandiz C, Carretero G, Daudén E, de la Cueva P, Gómez-García FJ, Herrera-Ceballos E, Belinchón-Romero I, Sánchez-Carazo JL, López-Estebaranz JL, Alsina M, Ferrán M, Torrado R, Carrascosa JM, Rivera R, Vanaclocha F; BIOBADADERM Study Group. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort. J Dermatolog Treat. 2016;27(3):203-9. doi: 10.3109/09546634.2015.1088130. Epub 2015 Sep 25.</citation>
    <PMID>26367799</PMID>
  </results_reference>
  <results_reference>
    <citation>Sanz-Bueno J, Vanaclocha F, García-Doval I, Torrado R, Carretero G, Daudén E, Patricia Ruiz-Genao D, Alsina-Gibert MM, Pérez-Zafrilla B, Pérez-Rial G, Rivera R; members of the BIOBADADERM group. Risk of Reactivation of Hepatitis B Virus Infection in Psoriasis Patients Treated With Biologics: A Retrospective Analysis of 20 Cases From the BIOBADADERM Database. Actas Dermosifiliogr. 2015 Jul-Aug;106(6):477-82. doi: 10.1016/j.ad.2015.01.010. Epub 2015 Mar 13. English, Spanish.</citation>
    <PMID>25776200</PMID>
  </results_reference>
  <results_reference>
    <citation>Carrascosa JM, Garcia-Doval I, Pérez-Zafrilla B, Carretero G, Vanaclocha F, Daudén E, De la Cueva-Dobao P, Belinchón I, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Rivera R, Carazo C, Barboza L, Ferrándiz C; BIOBADADERM Study Group. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice. J Dermatolog Treat. 2015;26(6):502-6. doi: 10.3109/09546634.2015.1034070. Epub 2015 Apr 17.</citation>
    <PMID>25886087</PMID>
  </results_reference>
  <results_reference>
    <citation>Carrascosa JM, Rivera N, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, De-la-Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, Alsina M, Sánchez-Carazo JL, Ferrán M, Lopez-Estebaranz JL, Pérez-Zafrilla B, Llamas M, Rivera R, Ferrándiz C; BIOBADADERM Study Group. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time. Actas Dermosifiliogr. 2015 Oct;106(8):638-43. doi: 10.1016/j.ad.2015.04.013. Epub 2015 Jun 30. English, Spanish.</citation>
    <PMID>26141003</PMID>
  </results_reference>
  <results_reference>
    <citation>Ruiz-Genao D, Perez-Zafrilla B, Lopez-Estebaranz JL, Belinchón-Romero I, Carrascosa JM, Ferrán M, Vanaclocha F, Herrera-Ceballos E, García-Doval I; Biobadaderm Study Group. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort. Br J Dermatol. 2017 Mar;176(3):797-799. doi: 10.1111/bjd.14690. Epub 2016 Oct 17.</citation>
    <PMID>27120993</PMID>
  </results_reference>
  <results_reference>
    <citation>García-Doval I, Hernández MV, Vanaclocha F, Sellas A, de la Cueva P, Montero D; BIOBADADERM and BIOBADASER study groups. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol. 2017 Mar;176(3):643-649. doi: 10.1111/bjd.14776. Epub 2016 Oct 3.</citation>
    <PMID>27258623</PMID>
  </results_reference>
  <results_reference>
    <citation>Dávila-Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Llamas M, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016 Nov;30(11):1942-1950. doi: 10.1111/jdv.13682. Epub 2016 Jun 22.</citation>
    <PMID>27329511</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2013</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>December 26, 2016</last_update_submitted>
  <last_update_submitted_qc>December 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>biologic therapy</keyword>
  <keyword>infliximab</keyword>
  <keyword>etanercept</keyword>
  <keyword>efalizumab</keyword>
  <keyword>adalimumab</keyword>
  <keyword>ustekinumab</keyword>
  <keyword>methotrexate</keyword>
  <keyword>cyclosporine</keyword>
  <keyword>acitretin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

